Symbols / HEPA $0.06 +10.00% Hepion Pharmaceuticals, Inc.
HEPA Chart
About
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 639.12K |
| Enterprise Value | 560.25K | Income | -8.28M | Sales | — |
| Book/sh | 0.08 | Cash/sh | 0.16 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | — | P/B | 0.65 | P/C | — |
| EV/EBITDA | -0.15 | EV/Sales | — | Quick Ratio | 6.11 |
| Current Ratio | 10.25 | Debt/Eq | 2.03 | LT Debt/Eq | — |
| EPS (ttm) | -0.88 | EPS next Y | -11.43 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-04-16 16:00 | ROA | -100.37% |
| ROE | -20.59% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 11.62M |
| Shs Float | 11.62M | Short Float | 4.10% | Short Ratio | 0.05 |
| Short Interest | — | 52W High | 0.99 | 52W Low | 0.03 |
| Beta | 1.94 | Avg Volume | 16.00K | Volume | 119.00 |
| Target Price | — | Recom | None | Prev Close | $0.05 |
| Price | $0.06 | Change | 10.00% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-12-07 | down | Brookline Capital | Buy → Hold | — |
- HEPA (Hepion Pharmaceuticals) 3-Year Share Buyback Ratio : -434.70% (As of Dec. 2025) - GuruFocus Sat, 28 Mar 2026 21
- Hepion Pharmaceuticals (OTC: HEPA) CEO exits as board installs new leaders - stocktitan.net Wed, 18 Mar 2026 07
- Gap Down: Is HEPA forming a breakout pattern - 2026 Stock Rankings & High Conviction Trade Alerts - baoquankhu1.vn Mon, 30 Mar 2026 19
- 8 Best Air Purifiers of 2026, Tested by Our Experts - Consumer Reports Wed, 18 Mar 2026 07
- Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - stocktitan.net Mon, 12 May 2025 07
- HEPA Filters Manufacturers and Suppliers in the USA – A Thomas Industry Overview - Thomasnet Fri, 21 Nov 2025 08
- Hepion Pharmaceuticals to be delisted from Nasdaq - investing.com Mon, 12 May 2025 07
- Hepion Pharmaceuticals Inc (HEPA) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus ue, 24 Mar 2026 10
- Semiconductor Cleanroom Market Report 2025 - 2030 [250 Pages & 160 Tables] - MarketsandMarkets hu, 09 Oct 2025 06
- Hepion Pharmaceuticals Stock (ISIN: US4268971032) Faces Uncertainty Amid Pipeline Delays and Biotech - AD HOC NEWS ue, 17 Mar 2026 07
- Dreo HEPA Air Purifier: $114 off during Walmart Deals event - PennLive.com ue, 07 Oct 2025 07
- Vincent LoPriore listed as Hepion (HEPA) director and Executive Chairman - stocktitan.net Wed, 18 Mar 2026 07
- 9 Best Upright Vacuums of 2026 - Consumer Reports hu, 01 Jan 2026 08
- HEPA (Hepion Pharmaceuticals) Non Operating Income : $-4.49 Mil (TTM As of Dec. 2025) - GuruFocus Sun, 29 Mar 2026 02
- Hepion Pharmaceuticals Stock (ISIN: US4268971032) Trades at $0.83 Amid Liver Disease Drug Developmen - AD HOC NEWS Wed, 18 Mar 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
3.76
-80.56%
|
19.35
-57.25%
|
45.26
+3.76%
|
43.62
|
| Research And Development |
|
0.45
-96.24%
|
11.85
-66.76%
|
35.64
+7.12%
|
33.27
|
| Selling General And Administration |
|
3.32
-55.79%
|
7.50
-22.03%
|
9.62
-7.06%
|
10.35
|
| General And Administrative Expense |
|
3.32
-55.79%
|
7.50
-22.03%
|
9.62
-7.06%
|
10.35
|
| Other Gand A |
|
3.32
-55.79%
|
7.50
-22.03%
|
9.62
-7.06%
|
10.35
|
| Total Expenses |
|
3.76
-80.56%
|
19.35
-57.25%
|
45.26
+3.76%
|
43.62
|
| Operating Income |
|
-3.76
+80.56%
|
-19.35
+57.25%
|
-45.26
-3.76%
|
-43.62
|
| Total Operating Income As Reported |
|
-4.16
+78.48%
|
-19.35
+60.07%
|
-48.45
-6.51%
|
-45.49
|
| EBITDA |
|
-8.25
+44.55%
|
-14.88
+69.78%
|
-49.26
-9.47%
|
-45.00
|
| Normalized EBITDA |
|
-3.76
+80.53%
|
-19.32
+57.26%
|
-45.19
-3.79%
|
-43.54
|
| Reconciled Depreciation |
|
0.00
-100.00%
|
0.03
-54.18%
|
0.07
-13.34%
|
0.08
|
| EBIT |
|
-8.25
+44.66%
|
-14.91
+69.76%
|
-49.33
-9.43%
|
-45.07
|
| Total Unusual Items |
|
-4.49
-201.36%
|
4.43
+208.96%
|
-4.07
-179.38%
|
-1.46
|
| Total Unusual Items Excluding Goodwill |
|
-4.49
-201.36%
|
4.43
+208.96%
|
-4.07
-179.38%
|
-1.46
|
| Special Income Charges |
|
-0.40
+87.28%
|
-3.17
+0.72%
|
-3.19
-70.50%
|
-1.87
|
| Other Special Charges |
|
—
|
2.57
|
—
|
—
|
| Impairment Of Capital Assets |
|
0.40
|
0.00
-100.00%
|
3.19
+70.50%
|
1.87
|
| Write Off |
|
0.00
-100.00%
|
0.60
|
0.00
|
—
|
| Net Income |
|
-8.28
+37.25%
|
-13.19
+73.04%
|
-48.93
-15.94%
|
-42.20
|
| Pretax Income |
|
-8.28
+48.78%
|
-16.16
+67.24%
|
-49.34
-9.43%
|
-45.08
|
| Net Non Operating Interest Income Expense |
|
-0.02
+98.04%
|
-1.25
-13078.16%
|
-0.01
+6.88%
|
-0.01
|
| Interest Expense Non Operating |
|
0.02
-98.04%
|
1.25
+13078.16%
|
0.01
-6.88%
|
0.01
|
| Net Interest Income |
|
-0.02
+98.04%
|
-1.25
-13078.16%
|
-0.01
+6.88%
|
-0.01
|
| Interest Expense |
|
0.02
-98.04%
|
1.25
+13078.16%
|
0.01
-6.88%
|
0.01
|
| Other Income Expense |
|
-4.49
-201.36%
|
4.43
+208.96%
|
-4.07
-179.38%
|
-1.46
|
| Gain On Sale Of Security |
|
-4.09
-153.82%
|
7.60
+965.87%
|
-0.88
-311.48%
|
0.41
|
| Tax Provision |
|
0.00
+100.00%
|
-2.97
-625.94%
|
-0.41
+85.82%
|
-2.88
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
+2196.52%
|
0.00
-87.50%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
-100.00%
|
0.81
+2602.36%
|
-0.03
+65.08%
|
-0.09
|
| Net Income Including Noncontrolling Interests |
|
-8.28
+37.25%
|
-13.19
+73.04%
|
-48.93
-15.94%
|
-42.20
|
| Net Income From Continuing Operation Net Minority Interest |
|
-8.28
+37.25%
|
-13.19
+73.04%
|
-48.93
-15.94%
|
-42.20
|
| Net Income From Continuing And Discontinued Operation |
|
-8.28
+37.25%
|
-13.19
+73.04%
|
-48.93
-15.94%
|
-42.20
|
| Net Income Continuous Operations |
|
-8.28
+37.25%
|
-13.19
+73.04%
|
-48.93
-15.94%
|
-42.20
|
| Normalized Income |
|
-3.79
+77.48%
|
-16.81
+62.55%
|
-44.89
-9.93%
|
-40.84
|
| Net Income Common Stockholders |
|
-8.28
+37.25%
|
-13.19
+73.04%
|
-48.93
-7.92%
|
-45.34
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
0.00
-100.00%
|
3.14
|
| Diluted EPS |
|
—
|
-2.15
+99.65%
|
-616.07
-3.54%
|
-595.00
|
| Basic EPS |
|
—
|
-2.15
+99.65%
|
-616.07
-3.54%
|
-595.00
|
| Basic Average Shares |
|
—
|
6.14
+7637.36%
|
0.08
+4.18%
|
0.08
|
| Diluted Average Shares |
|
—
|
6.14
+7637.36%
|
0.08
+4.18%
|
0.08
|
| Diluted NI Availto Com Stockholders |
|
-8.28
+37.25%
|
-13.19
+73.04%
|
-48.93
-7.92%
|
-45.34
|
| Preferred Stock Dividends |
|
—
|
—
|
—
|
3.14
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
3.07
+90.24%
|
1.61
-91.08%
|
18.09
-69.97%
|
60.24
|
| Current Assets |
|
3.07
+90.24%
|
1.61
-90.77%
|
17.49
-69.05%
|
56.50
|
| Cash Cash Equivalents And Short Term Investments |
|
1.83
+349.81%
|
0.41
-97.25%
|
14.79
-71.12%
|
51.19
|
| Cash And Cash Equivalents |
|
1.83
+349.81%
|
0.41
-97.25%
|
14.79
-71.12%
|
51.19
|
| Cash Financial |
|
1.83
+349.81%
|
0.41
-97.25%
|
14.79
-71.12%
|
51.19
|
| Prepaid Assets |
|
1.24
+2.86%
|
1.21
-55.32%
|
2.70
-49.09%
|
5.31
|
| Total Non Current Assets |
|
0.00
|
0.00
-100.00%
|
0.61
-83.82%
|
3.75
|
| Net PPE |
|
—
|
-0.00
-100.00%
|
0.24
-92.70%
|
3.32
|
| Gross PPE |
|
—
|
0.42
-32.34%
|
0.62
-82.87%
|
3.63
|
| Accumulated Depreciation |
|
—
|
-0.42
-10.87%
|
-0.38
-23.63%
|
-0.31
|
| Properties |
|
—
|
—
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
0.21
-93.43%
|
3.24
|
| Machinery Furniture Equipment |
|
—
|
0.06
+0.00%
|
0.06
+0.00%
|
0.06
|
| Other Properties |
|
—
|
0.36
-35.93%
|
0.56
+71.47%
|
0.33
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
0.00
-100.00%
|
3.19
|
| Goodwill |
|
—
|
—
|
—
|
0.00
|
| Other Intangible Assets |
|
—
|
—
|
—
|
3.19
|
| Other Non Current Assets |
|
—
|
—
|
0.36
-14.54%
|
0.43
|
| Total Liabilities Net Minority Interest |
|
0.40
-88.43%
|
3.48
-67.85%
|
10.81
+4.09%
|
10.39
|
| Current Liabilities |
|
0.30
-90.48%
|
3.14
-40.57%
|
5.29
-32.92%
|
7.89
|
| Payables And Accrued Expenses |
|
0.25
+0.59%
|
0.24
-94.91%
|
4.79
-13.87%
|
5.56
|
| Payables |
|
0.17
-23.79%
|
0.22
-90.63%
|
2.35
-11.89%
|
2.67
|
| Accounts Payable |
|
0.17
-23.79%
|
0.22
-90.63%
|
2.35
-11.89%
|
2.67
|
| Current Accrued Expenses |
|
0.08
+227.25%
|
0.02
-99.03%
|
2.44
-15.70%
|
2.89
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
—
|
0.00
-100.00%
|
1.91
|
| Total Tax Payable |
|
—
|
—
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.05
-98.14%
|
2.90
+2401.81%
|
0.12
+116.20%
|
0.05
|
| Current Debt |
|
0.05
-98.14%
|
2.90
|
—
|
—
|
| Current Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.12
+116.20%
|
0.05
|
| Other Current Liabilities |
|
—
|
—
|
0.39
+5.40%
|
0.37
|
| Total Non Current Liabilities Net Minority Interest |
|
0.10
-69.08%
|
0.33
-93.97%
|
5.52
+120.69%
|
2.50
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.09
|
0.00
|
| Long Term Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.09
|
0.00
|
| Non Current Deferred Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.41
|
| Non Current Deferred Taxes Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.41
|
| Other Non Current Liabilities |
|
—
|
—
|
1.63
-21.96%
|
2.09
|
| Stockholders Equity |
|
2.67
+243.16%
|
-1.86
-125.59%
|
7.28
-85.40%
|
49.86
|
| Common Stock Equity |
|
0.97
+127.33%
|
-3.56
-163.71%
|
5.59
-88.40%
|
48.16
|
| Capital Stock |
|
1.70
+0.07%
|
1.70
+0.00%
|
1.70
-0.08%
|
1.70
|
| Common Stock |
|
0.00
+8200.00%
|
0.00
+40.00%
|
0.00
-97.38%
|
0.00
|
| Preferred Stock |
|
1.70
+0.00%
|
1.70
+0.00%
|
1.70
-0.06%
|
1.70
|
| Share Issued |
|
11.62
+8249.85%
|
0.14
+44.40%
|
0.10
+26.43%
|
0.08
|
| Ordinary Shares Number |
|
11.62
+8249.85%
|
0.14
+44.40%
|
0.10
+26.43%
|
0.08
|
| Additional Paid In Capital |
|
247.06
+5.47%
|
234.25
+1.72%
|
230.29
+2.83%
|
223.95
|
| Retained Earnings |
|
-246.10
-3.48%
|
-237.82
-5.87%
|
-224.63
-27.85%
|
-175.70
|
| Gains Losses Not Affecting Retained Earnings |
|
0.01
+0.00%
|
0.01
+110.59%
|
-0.08
+12.63%
|
-0.09
|
| Other Equity Adjustments |
|
0.01
+0.00%
|
0.01
+110.59%
|
-0.08
+12.63%
|
-0.09
|
| Total Equity Gross Minority Interest |
|
2.67
+243.16%
|
-1.86
-125.59%
|
7.28
-85.40%
|
49.86
|
| Total Capitalization |
|
2.67
+243.16%
|
-1.86
-125.59%
|
7.28
-85.40%
|
49.86
|
| Working Capital |
|
2.77
+281.07%
|
-1.53
-112.54%
|
12.20
-74.91%
|
48.61
|
| Invested Capital |
|
1.03
+255.89%
|
-0.66
-111.79%
|
5.59
-88.40%
|
48.16
|
| Total Debt |
|
0.05
-98.14%
|
2.90
+1287.43%
|
0.21
+289.86%
|
0.05
|
| Net Debt |
|
—
|
2.49
|
—
|
—
|
| Capital Lease Obligations |
|
—
|
0.00
-100.00%
|
0.21
+289.86%
|
0.05
|
| Net Tangible Assets |
|
2.67
+243.16%
|
-1.86
-125.59%
|
7.28
-85.40%
|
49.86
|
| Tangible Book Value |
|
0.97
+127.33%
|
-3.56
-163.71%
|
5.59
-88.40%
|
48.16
|
| Current Notes Payable |
|
0.05
-98.14%
|
2.90
|
0.00
|
—
|
| Derivative Product Liabilities |
|
0.10
-69.08%
|
0.33
-91.22%
|
3.80
|
0.00
|
| Preferred Shares Number |
|
0.09
+0.00%
|
0.09
+0.00%
|
0.09
-0.13%
|
0.09
|
| Preferred Stock Equity |
|
1.70
+0.00%
|
1.70
+0.00%
|
1.70
-0.06%
|
1.70
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-3.27
+82.04%
|
-18.22
+55.45%
|
-40.89
-16.96%
|
-34.96
|
| Cash Flow From Continuing Operating Activities |
|
-3.27
+82.04%
|
-18.22
+55.45%
|
-40.89
-16.96%
|
-34.96
|
| Net Income From Continuing Operations |
|
-8.28
+37.25%
|
-13.19
+73.04%
|
-48.93
-15.94%
|
-42.20
|
| Depreciation Amortization Depletion |
|
0.00
-100.00%
|
0.03
-54.18%
|
0.07
-13.34%
|
0.08
|
| Depreciation |
|
0.00
-100.00%
|
0.03
-54.18%
|
0.07
|
—
|
| Depreciation And Amortization |
|
0.00
-100.00%
|
0.03
-54.18%
|
0.07
-13.34%
|
0.08
|
| Other Non Cash Items |
|
—
|
1.82
+512.70%
|
-0.44
-6.03%
|
-0.41
|
| Stock Based Compensation |
|
0.02
-97.37%
|
0.79
-40.94%
|
1.34
-47.50%
|
2.55
|
| Asset Impairment Charge |
|
0.40
-32.88%
|
0.60
-81.19%
|
3.19
+70.50%
|
1.87
|
| Deferred Tax |
|
—
|
0.00
+100.00%
|
-0.41
|
0.00
|
| Deferred Income Tax |
|
—
|
0.00
+100.00%
|
-0.41
|
0.00
|
| Operating Gains Losses |
|
4.09
+173.30%
|
-5.58
-523.43%
|
1.32
|
—
|
| Gain Loss On Investment Securities |
|
4.09
+173.30%
|
-5.58
-523.43%
|
1.32
|
—
|
| Change In Working Capital |
|
0.49
+118.38%
|
-2.68
-190.30%
|
2.97
-5.76%
|
3.15
|
| Change In Prepaid Assets |
|
0.49
-73.55%
|
1.86
-30.51%
|
2.68
+191.62%
|
0.92
|
| Change In Payables And Accrued Expense |
|
0.00
+100.03%
|
-4.55
-1600.59%
|
0.30
-86.51%
|
2.25
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
—
|
| Change In Other Current Assets |
|
0.00
-100.00%
|
0.21
+136.99%
|
0.09
-64.51%
|
0.25
|
| Change In Other Current Liabilities |
|
0.00
+100.00%
|
-0.21
-116.13%
|
-0.10
+63.28%
|
-0.26
|
| Investing Cash Flow |
|
-0.13
+77.98%
|
-0.60
-4094.63%
|
-0.01
-1.66%
|
-0.01
|
| Cash Flow From Continuing Investing Activities |
|
-0.13
+77.98%
|
-0.60
-4094.63%
|
-0.01
-1.66%
|
-0.01
|
| Net PPE Purchase And Sale |
|
—
|
0.00
+100.00%
|
-0.01
-1.66%
|
-0.01
|
| Purchase Of PPE |
|
—
|
0.00
+100.00%
|
-0.01
+12.44%
|
-0.02
|
| Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Capital Expenditure |
|
—
|
—
|
-0.01
+12.44%
|
-0.02
|
| Net Investment Purchase And Sale |
|
-0.13
|
0.00
|
—
|
—
|
| Purchase Of Investment |
|
-0.13
|
0.00
|
—
|
—
|
| Net Other Investing Changes |
|
—
|
-0.60
|
—
|
—
|
| Financing Cash Flow |
|
4.83
+10.93%
|
4.35
-3.23%
|
4.49
+187.49%
|
-5.14
|
| Cash Flow From Continuing Financing Activities |
|
4.83
+10.93%
|
4.35
-3.23%
|
4.49
+187.49%
|
-5.14
|
| Net Issuance Payments Of Debt |
|
-3.37
|
0.00
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
-3.37
|
0.00
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
-3.37
|
0.00
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
-3.37
|
0.00
|
—
|
0.00
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
2.50
|
0.00
|
0.00
|
| Repurchase Of Capital Stock |
|
—
|
—
|
0.00
+100.00%
|
-21.00
|
| Proceeds From Stock Option Exercised |
|
9.00
+386.56%
|
1.85
-58.85%
|
4.49
|
0.00
|
| Net Other Financing Charges |
|
-0.80
|
—
|
—
|
-2.00
|
| Changes In Cash |
|
1.42
+109.83%
|
-14.47
+60.27%
|
-36.41
+9.24%
|
-40.11
|
| Effect Of Exchange Rate Changes |
|
0.00
-100.00%
|
0.09
+1634.16%
|
0.01
+110.66%
|
-0.05
|
| Beginning Cash Position |
|
0.41
-97.25%
|
14.79
-71.12%
|
51.19
-43.96%
|
91.35
|
| End Cash Position |
|
1.83
+349.81%
|
0.41
-97.25%
|
14.79
-71.12%
|
51.19
|
| Free Cash Flow |
|
-3.27
+82.04%
|
-18.22
+55.46%
|
-40.90
-16.94%
|
-34.98
|
| Interest Paid Supplemental Data |
|
0.02
|
0.00
|
0.00
-100.00%
|
0.00
|
| Common Stock Issuance |
|
0.00
-100.00%
|
2.50
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
2.50
|
0.00
-100.00%
|
17.86
|
| Net Preferred Stock Issuance |
|
—
|
—
|
0.00
+100.00%
|
-3.14
|
| Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
17.86
|
| Preferred Stock Payments |
|
—
|
—
|
0.00
+100.00%
|
-21.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-18 View
- 10-K2026-03-12 View
- 8-K2026-03-03 View
- 8-K2026-01-15 View
- 10-Q2025-11-12 View
- 10-Q2025-08-14 View
- 8-K2025-06-30 View
- 8-K2025-06-12 View
- 8-K2025-06-09 View
- 8-K2025-05-30 View
- 10-Q2025-05-19 View
- 8-K2025-05-12 View
- 8-K2025-05-06 View
- 8-K2025-04-17 View
- 10-K2025-04-08 View
- 8-K2025-03-20 View
- 8-K2025-03-19 View
- 8-K2025-03-10 View
- 8-K2025-03-04 View
- 8-K2025-01-15 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|